Morgan Stanley
GEVA

Morgan Stanley’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Morgan Stanley’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-15,826
Closed -$1.54M – 6945
2015
Q1 		$1.54M Sell
15,826
-271
-2% -$28.7K ﹤0.01% 3801
2014
Q4 		$1.49M Sell
16,097
-6,913
-30% -$546K ﹤0.01% 3802
2014
Q3 		$1.58M Sell
23,010
-4,854
-17% -$348K ﹤0.01% 3629
2014
Q2 		$2.92M Buy
27,864
+16,732
+150% +$1.42M ﹤0.01% 3175
2014
Q1 		$922K Sell
11,132
-20,292
-65% -$1.88M ﹤0.01% 4059
2013
Q4 		$2.03M Buy
31,424
+15,139
+93% +$899K ﹤0.01% 3367
2013
Q3 		$1.03M Sell
16,285
-7,784
-32% -$383K ﹤0.01% 3762
2013
Q2 		$1.01M Buy
+24,069
New +$1.1M ﹤0.01% 3726

Morgan Stanley's GEVA Position: Q2 2015 in Review

Morgan Stanley sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 15,826 shares — an estimated $1.54M sold.

Morgan Stanley first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $2.92M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Morgan Stanley reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Morgan Stanley sold 15,826 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $1.54M.
  • Morgan Stanley first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Morgan Stanley's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $2.92M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Morgan Stanley's 13F filing for Q2 2015, filed 12 Aug 2015.